VivoSeq
Oncology

Gallbladder Carcinoma

19

Pipeline Programs↗

1

Active Trials↗

14

Companies Involved↗

Gallbladder Carcinoma is an emerging landscape with 19 programs across 14 companies. The most active players are Boehringer Ingelheim, Novartis, Imclone. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

2 programs

Phase 2Novartis logo

Novartis

1 program

Phase 2I

Imclone

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

90%

Small molecule

19 of 21 classified programs — the dominant modality here.

10%ALL OTHERSMonoclonal antibody210%

Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 100% of 23 pipeline programs.

Analysis

Trial Status

9

clinical trials

Unknown status5 · 56%
Completed3 · 33%
Recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA
Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT04183712·102 enrolled
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
Completed·AAIO-Studien-gGmbH·Phase 2·NCT03043547·100 enrolled
Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC
Completed·—·Phase 3·NCT03673072·68 enrolled
New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma
Completed·SShanghai Jiao Tong University School of Medicine·Phase 3·NCT01053390·216 enrolled
Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT03772132·100 enrolled
Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma
Unknown status·FFudan University·Phase 3·NCT02798510·140 enrolled
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT02836847·152 enrolled
Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT03768375·150 enrolled
Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma
Unknown status·—·Phase 2·NCT03702491·138 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)